| Indications: |
Raltegravir, brand name Isentress, is a first-in-its-class oral integrase inhibitor that prevents HIV-1 replication by inhibiting the insertion of virally encoded DNA into the human genome. The addition of raltegravir to optimized background therapy in treatment-experienced HIV infected patients results in significant reductions in HIV firal loads and increased CD4 counts (for review see Hicks and Glick. Clin Infect Dls. 2009:48(7):931-9). However, in a recent study, nearly one quarter of raltegravir treated patients developed virologic failure associated with genotype evidence of integrase resistance (Cooper et al. N Engl J Med. 2008: 359(4):355-65). |
